NXTC_OUT_1 [2025-04-28 05:46:16 -0400] 5819 Bytes | 1615 tokens | Cum: 1615 tkns (20.19% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at NextCure (NXTC) which is at $0.4900 up from $0.4600. So, I pulled together a bunch of data for you to look over real fast. It's still early, 5:46 AM on Mon Apr 28, 2025. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: NextCure (NXTC)
IPO: 2019-05-09 (5 Years Ago)
Market Cap: $7,701,838
Shares Outstanding: 28,010,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Here’s a list of headlines for NextCure:

Apr-04-25 07:00AM - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
Mar-06-25 04:05PM - NextCure Provides Business Update and Reports Full Year 2024 Financial Results
Jan-10-25 08:05AM - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
Dec-10-24 08:05AM - NextCure Announces Acceptance of IND Application for LNCB74
Nov-26-24 07:00AM - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
Nov-19-24 08:05AM - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
Nov-08-24 06:18AM - NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space
Nov-07-24 04:05PM - NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
Nov-05-24 04:05PM - NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
Oct-04-24 09:05AM - NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
Sep-16-24 08:05AM - NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Aug-01-24 04:05PM - NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
Jun-20-24 04:10PM - NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
May-30-24 04:05PM - NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May-02-24 09:57PM - NXTC Stock Earnings: NextCure Misses EPS for Q1 2024
May-02-24 09:57PM 04:05PM - NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
Apr-24-24 04:05PM - NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
Apr-08-24 07:00AM - NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Apr-04-24 07:05AM - NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
Apr-02-24 07:00AM - NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
Mar-23-24 06:00AM - Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
Mar-21-24 10:54PM - NXTC Stock Earnings: NextCure Beats EPS for Q4 2023

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-04T11:00:00Z - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
B2 - 2024-11-26T12:00:00Z - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
B3 - 2024-06-20T20:10:00Z - NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
B4 - 2024-04-24T20:05:00Z - NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
B5 - 2024-04-08T11:00:00Z - NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
B6 - 2024-04-04T11:05:00Z - NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for NextCure (NXTC).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NXTC_OUT_3 [2025-04-28 05:46:17 -0400] 832 Bytes | 226 tokens | Cum: 1843 tkns (23.04% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**NextCure to Present at 24th Annual Needham Virtual Healthcare Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/04/3055856/0/en/NextCure-to-Present-at-24th-Annual-Needham-Virtual-Healthcare-Conference.htmlNextCure, a clinical-stage biopharmaceutical company, announced the completion of cohort 1 of the Phase 1 trial for its B7-H4 ADC drug candidate and plans to initiate backfill cohorts in the second half of 2025. The company reported a cash position of approximately $68.6 million.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NXTC_OUT_5 [2025-04-28 05:46:18 -0400] 933 Bytes | 275 tokens | Cum: 2120 tkns (26.50% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-09T21:05:58Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Autolus Therapeutics (NASDAQ:AUTL...
A2 - 2025-04-09T17:32:06Z - NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com...
A3 - 2025-04-09T17:32:06Z - NextCure stock hits 52-week low at $0.3 amid sharp decline By Investing.com...
A4 - 2025-04-04T11:03:19Z - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference...
A5 - 2025-04-04T11:13:57Z - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NXTC_OUT_7 [2025-04-28 05:46:19 -0400] 1181 Bytes | 346 tokens | Cum: 2468 tkns (30.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Wednesday's After-Market Session - Autolus Therapeutics (NASDAQ:AUTL), Artiva Biotherapeutics (NASDAQ:ARTV)**Date: 2025-04-09Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44724418/12-health-care-stocks-moving-in-wednesdays-after-market-sessionGainers

Reshape Lifesciences RSLS shares increased by 82.0% to $0.62 during Wednesday's after-market session. The market value of their outstanding shares is at $2.0 million. Processa Pharmaceuticals PCSA stock rose 16.98% to $0.31. The market value of their outstanding shares is at $1.6 million. Dogwood Therapeutics DWTX shares increased by 16.06% to $3.83. The company's market cap stands at $7.3 million. Autolus Therapeutics AUTL stock rose 13.22% to $1.37. The market value of their outstanding shares is at $364.5 million. NextCure

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NXTC_OUT_9 [2025-04-28 05:46:19 -0400] 1181 Bytes | 357 tokens | Cum: 2827 tkns (35.34% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): NXTC stock rose 11.21% to $0.33. The market value of their outstanding shares is at $9.1 million. 60 Degrees SXTP shares moved upwards by 8.8% to $2.72. The company's market cap stands at $4.0 million.

Losers

Venus Concept VERO shares fell 46.2% to $4.8 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. ENDRA Life Sciences NDRA stock decreased by 19.3% to $4.1. The company's market cap stands at $2.2 million. Lucid Diagnostics LUCD stock declined by 18.19% to $1.35. The company's market cap stands at $122.5 million. LogicMark LGMK stock fell 17.6% to $0.01. Pediatrix Medical Group MD shares decreased by 17.17% to $11.68. The company's market cap stands at $1.0 billion. Artiva Biotherapeutics ARTV stock decreased by 11.05% to $1.77. The company's market cap stands at $43.1 million. See Also: www.benzinga.com/money/best-healthcare-st

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NXTC_OUT_11 [2025-04-28 05:46:20 -0400] 1165 Bytes | 374 tokens | Cum: 3203 tkns (40.04% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTVArtiva Biotherapeutics Inc

$1.77-7.80%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full Score

Edge Rankings

Momentum

-

Growth

-

Quality

-

Value

4.90

Price Trend

Short

Medium

Long

Overview

AUTLAutolus Therapeutics PLC

$1.3716.1%

DWTXDogwood Therapeutics Inc

$4.3520.5%

LGMKLogicMark Inc

$0.00900-28.6%

LUCDLucid Diagnostics Inc

$1.33-17.9%

MDPediatrix Medical Group Inc

$11.68-12.0%

NDRAENDRA Life Sciences Inc

$4.000.25%

NXTCNextCure Inc

$0.3252-1.36%

PCSAProcessa Pharmaceuticals Inc

$0.299925.4%

RSLSReshape Lifesciences Inc

$0.649171.3%

SXTP60 Degrees Pharmaceuticals Inc

$2.60-9.41%

VEROVenus Concept Inc

$4.9268.5%

Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NXTC_OUT_13 [2025-04-28 05:46:21 -0400] 1110 Bytes | 284 tokens | Cum: 3489 tkns (43.61% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-10 8-K Item 7.01 Regulation FD Disclosure

On April 10, 2025, NextCure, Inc. (the Company) updated its corporate presentation to reflect updates on its ongoing clinical trial of LNCB74. Beginning on April 10, 2025, the Company will be engaging with members of the investment community, ...

S2 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and the related notes appearing elsewhe...

S3 - 2025-03-06 8-K Item 2.02 Results of Oper and Fin Cond

On March 6, 2025, NextCure, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2024. The Company is furnishing a copy of the press release, which is attached hereto a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NXTC_OUT_15 [2025-04-28 05:46:22 -0400] 1099 Bytes | 263 tokens | Cum: 3754 tkns (46.92% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure

On April 10, 2025, NextCure, Inc. (the Company) updated its corporate presentation to reflect updates on its ongoing clinical trial of LNCB74. Beginning on April 10, 2025, the Company will be engaging with members of the investment community, which may reference these presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be filed for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NXTC_OUT_17 [2025-04-28 05:46:29 -0400] 6850 Bytes | 1879 tokens | Cum: 5635 tkns (70.44% of 8k)
==========================================================================

This is our set of metrics for NextCure.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 322,824 | Perf Month: -13.45% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 132.18K | Perf Quarter: -44.11% | Short Float: 0.16% | ROE: -61.87% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 2.49 | Index: - | Short Ratio: 0.27 | ROI: -78.80% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 52.77 | Market Cap: 12.88M | Short Interest: 0.04M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.07 | Shs Outstand: 28.01M | Beta: 1.04 | EPS Surprise: -16.67% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 21.35% | Shs Float: 21.84M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -18.74% | Inst Own: 38.46% | Sales past 5Y: 30.52% | Earnings: Mar 06 AMC |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -57.82% | Insider Own: 22.02% | Employees: 43 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 27.35% | Insider Trans: 0.00% | Debt/Eq: 0.09 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by NextCure officers or majority shareholders (if available).

No transactions recorded.

Inside Trans: NextCure, Inc. (NXTC) by Richman Michael (President & CEO) on 2025-01-31
- Employee Stock Option (Right to Buy): 305500 shares at $0 (D)

Inside Trans: NextCure, Inc. (NXTC) by Cobourn Steven P. (Chief Financial Officer) on 2025-01-31
- Employee Stock Option (Right to Buy): 117375 shares at $0 (D)

Inside Trans: NextCure, Inc. (NXTC) by Kundu Sourav (Sr VP, Dev. & Mfg.) on 2025-01-31
- Employee Stock Option (Right to Buy): 66125 shares at $0 (D)

Inside Trans: NextCure, Inc. (NXTC) by Langermann Sol (Chief Scientific Officer) on 2025-01-31
- Employee Stock Option (Right to Buy): 117375 shares at $0 (D)

Inside Trans: NextCure, Inc. (NXTC) by Mayer Timothy (Chief Operating Officer) on 2025-01-31
- Employee Stock Option (Right to Buy): 117375 shares at $0 (D)

Inside Trans: NextCure, Inc. (NXTC) by Shaw Kevin G. (Sr VP, General Counsel) on 2025-01-31
- Employee Stock Option (Right to Buy): 66125 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -55654000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.46
Average Volume: 281400.74
30-Day High: 0.4803
30-Day Low: 0.27

[Detailed Financials: TTM 2024]
- Total Assets: $80,860,000.00
- Total Liabilities: $15,388,000.00
- Total Equity: $65,472,000.00
- Current Assets: $71,807,000.00
- Current Liabilities: $9,574,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-55,654,000.00
- Gross Profit: N/A
- Operating Income: $-59,748,000.00
- Earnings Per Share (EPS): -1.99

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $14,645,000.00

[Detailed Financials: FY 2024]
- Total Assets: $80,860,000.00
- Total Liabilities: $15,388,000.00
- Total Equity: $65,472,000.00
- Current Assets: $71,807,000.00
- Current Liabilities: $9,574,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-55,654,000.00
- Gross Profit: N/A
- Operating Income: $-59,748,000.00
- Earnings Per Share (EPS): -1.99

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $14,645,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of NextCure (NXTC).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about NextCure.

2) MARKET_SCORE[]
This conversation was initiated because NXTC is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NXTC.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NXTC could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NXTC to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of NextCure.

11) ETHICAL_RATING[]
Rate NextCure’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of NextCure.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NXTC_IN_19 [2025-04-28 05:46:29 -0400] 126 Bytes | 29 tokens | Cum: 5873 tkns (73.41% of 8k)
==========================================================================

====================================
[2025-04-28 05:46:29] # Analysis Completed
Elapsed Time: 14.02 seconds